title: Intradermal vaccination of dendritic cell-derived exosomes is superior to a subcutaneous one in the induction of antitumor immunity.
abstract: Because dendritic cell (DC)-derived exosomes (EXO) harbor many important DC molecules involved in inducing immune responses, EXO-based vaccines have been extensively used to induce antitumor immunity in different animal tumor models. However, it is not clear which route of EXO administration can induce more efficient antitumor immune responses. In this study, we compared the antitumor immunity derived from EXO vaccine by way of the two common administration routes, the subcutaneous (s.c.) and the intradermal (i.d.) administrations. Our data showed that the i.d. EXO administration resulted in more EXO-absorbed DC migrating into the T-cell areas of draining lymph nodes than the s.c. administration. Interestingly, the i.d. EXO administration also resulted in an enhanced ovalbumin (OVA)-specific CD8(+) T-cell proliferation and CD8(+) CTL effector responses in vivo, compared to the s.c. administration. Similarly, compared to the s.c. vaccination, the i.d. vaccination induced stronger antitumor immunity in the animal tumor model. Therefore, the i.d. EXO vaccination is superior to the s.c. one and should be considered when EXO-based vaccine is designed.
authors.affiliation: Research Unit, Division of Health Research, Saskatchewan Cancer Agency, Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
authors.forename: Siguo
authors.initials: S
authors.lastname: Hao
authors.forename: Zhenmin
authors.initials: Z
authors.lastname: Ye
authors.forename: Jicheng
authors.initials: J
authors.lastname: Yang
authors.forename: Ou
authors.initials: O
authors.lastname: Bai
authors.forename: Jim
authors.initials: J
authors.lastname: Xiang
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology* / Q000473:pathology; D005260:Female; D007167:Immunotherapy / Q000379:methods*; D007271:Injections, Intradermal; D007279:Injections, Subcutaneous; D051379:Mice; D008810:Mice, Inbred C57BL; D010641:Phenotype; D013945:Thymoma / Q000276:immunology* / Q000628:therapy*; D013953:Thymus Neoplasms / Q000276:immunology* / Q000628:therapy*; D022161:Transport Vesicles / Q000276:immunology*
chemical_list: D019496:Cancer Vaccines